IMIDomics, Inc. Announces Strategic Investment from Drug Discovery and Research Leader Evotec SE
Evotec SE (NASDAQ: EVO) has made an equity investment in IMIDomics, Inc., a biotechnology firm focusing on treatments for immune-mediated inflammatory diseases (IMIDs). The investment will allow Evotec to participate in IMIDomics' board of directors while supporting the advancement of its Precision Discovery™ Engine. This initiative integrates patient biological data and clinical expertise to identify effective treatments for over 17,000 IMID patients. The collaboration aims to develop targeted medicines addressing unmet medical needs in the field.
- Evotec's investment supports IMIDomics' Precision Discovery™ Engine for advanced treatment development.
- Partnership includes access to data from over 17,000 IMID patients, enhancing research capabilities.
- None.
IMIDs affect nearly 1 in 10 people – limiting quality of life and creating significant challenges to physical and mental well-being. The complexity of these diseases means even getting a diagnosis can be a long-term struggle for patients, and then finding a treatment that works can be a frustrating, time-consuming trial and error process.
This new investment will further advance IMIDomics’ Precision Discovery™ Engine which enables a deep understanding of how IMIDs work within patients via a combination of clinical and computational expertise with patient biological samples from the Vall d’Hebron Hospital IMID Biobank, exclusive access to curated, secure and anonymized clinical data collected from more than 17,000 IMID patients and control subjects from across 150 health centers, and proprietary biomolecular signatures generated by IMIDomics from these same patients. Ultimately, the Engine’s purpose is to discover medicines that will materially impact IMID patients’ lives.
“Evotec and IMIDomics are perfectly aligned on their goal to leverage data to discover and develop precise-acting, effective medicines of the future,” said Dr.
“The still unmet needs in this immense and ever-expanding category of illnesses demand that we leverage patient data holistically to decipher the causes of disease and find treatments. Evotec’s dedication to the use of data in drug discovery is why they are such a strong fit with IMIDomics – they share our core mission of applying intersectional data to uncover the next generation of targeted medicines and companion diagnostic tools needed to more precisely address complex IMID diseases and positively impact the experience and outcomes for people living with them,” said
IMIDomics was founded in
To learn more about IMIDomics, please visit www.imidomics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220215005553/en/
IMIDomics Press Contact:
saranda@realchemistry.com
Source:
FAQ
What is the significance of Evotec's investment in IMIDomics?
How does Evotec plan to leverage the investment in IMIDomics?
What is the role of the Evotec representative on the IMIDomics board?
What is the current focus of IMIDomics?